510(k) Report

510(k) · Cleared

Cleared

Motivista (CT-155)

K254038510(k) TraditionalCleared Jul 30, 2026226-day reviewClass II21 CFR 882.5801

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Click Therapeutics, Inc. · SAP Computerized Behavioral Therapy Device For Depressive Disorders.

Cleared on Jul 30, 2026 as substantially equivalent to K231209 (Otsuka America Pharmaceutical, Inc., 2024) after a 226-day review. Its family tree reaches back 2 generations to 2017.

Decided
Jul 30, 2026
Review
226 days
Class
Class II
Product code
SAP
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN160018 (2017). No later device cites it as a predicate yet.

DEN160018 · reSet · Pear Therapeutics, Inc. · 2017K231209 · Rejoyn · Otsuka America Pharmaceutical, Inc. · 20242016201820202022202420262028
  1. Root · 2 generations backDEN160018 reSetPear Therapeutics, Inc. · 2017
  2. 1 generation backK231209 RejoynOtsuka America Pharmaceutical, Inc. · 2024
  3. This deviceK254038 Motivista (CT-155)Click Therapeutics, Inc. · 2026
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN160018reSetPear Therapeutics, Inc.2017—
−1K231209RejoynOtsuka America Pharmaceutical, Inc.2024—
0 (this device)K254038Motivista (CT-155)Click Therapeutics, Inc.2026—
FIG. 1 — Lineage of K254038, 2017–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in SAP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new SAP device

  1. #1 K231209 Rejoynscore 10.1 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K231209Rejoyn
Summary page 5
…Device Type: Prescription Digital Therapeutic Device Manufacturer: Otsuka America Pharmaceutical, Inc. Premarket Notification Number: K231209 Device Classification: 21 CFR 882.5801, Computerized Behavioral Therapy Device for Psychiatric…
Otsuka America Pharmaceutical, Inc.2024—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 9 years and passes through 3 companies; a new generation was cleared every 6.5 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All SAP devices

SAP Computerized Behavioral Therapy Device For Depressive Disorders.: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · SAP

2in 2024

2024: 22026 (partial year): 1
2007high 2 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · SAP

Too few SAP 510(k)s in any year since 2007 to give a median.

Recalls per year · SAP

No recall names SAP since 2007.

Adverse event reports per year · SAP

No MAUDE report names SAP since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20242—00
20250—00
20261—0—

What is it indicated for?

Motivista (CT-155) is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K254038: Motivista (CT-155).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K254038

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded Oct 30, 2026
  • Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026